Federal:
HELP Copays Act: Congress was in recess for August and returned just after Labor Day. The All Copays Count Coalition continues to work with Congressional offices regarding H.R. 830 and S. 1375.…
In a win for the National Bleeding Disorders Foundation (NBDF) and the bleeding disorders community at large, on September 29, the United States District Court for the District of Columbia ruled that insurers can no longer…
A recent publication in the journal Haemophilia, represents a great opportunity to shed light on an ultra-rare condition that is perhaps lesser known to the broader bleeding disorders community. The article’s focus is the sole therapy approved by…
Results of a new study published in the journal Haemophilia are illustrative of persistent health disparities existing within the U.S. hemophilia population.
The data that informed the study was drawn from National Vital…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to TI-168, a T-cell therapy developed by Baudax Bio to treat people with hemophilia A and an inhibitor. ODD, which is granted by the FDA’s Office of Orphan…
Some compelling results from the ‘Hemophilia Life Stages and Changes Global Survey’ were recently announced in a new press release. The survey was conducted by a global market research firm The Harris Poll and sponsored by Sanofi.
More than 2,700…